Samsung Biologics Co Ltd
KRX:207940
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Samsung Biologics Co Ltd
KRX:207940
|
KR |
|
D
|
Directa SIM SpA
F:ZP7
|
IT |
|
Regal Rexnord Corp
NYSE:RRX
|
US |
|
G
|
Grenevia SA
WSE:GEA
|
PL |
|
Olin Corp
NYSE:OLN
|
US |
|
National Storage Affiliates Trust
NYSE:NSA
|
US |
|
Hoya Corp
TSE:7741
|
JP |
|
Farmer Bros Co
NASDAQ:FARM
|
US |
|
U-Next Holdings Co Ltd
OTC:USNNF
|
JP |
|
Repay Holdings Corp
NASDAQ:RPAY
|
US |
|
Kidoz Inc
XTSX:KDOZ
|
CA |
|
Universal Music Group NV
AEX:UMG
|
NL |
|
Parsons Corp
NYSE:PSN
|
US |
|
ANSYS Inc
NASDAQ:ANSS
|
US |
|
ManpowerGroup Inc
NYSE:MAN
|
US |
|
W R Berkley Corp
NYSE:WRB
|
US |
|
Full Truck Alliance Co Ltd
NYSE:YMM
|
CN |
|
C
|
Cerner Corp
LSE:0R00
|
US |
|
Toronto-Dominion Bank
TSX:TD
|
CA |
|
Guangdong Investment Ltd
HKEX:270
|
HK |
|
Diageo PLC
LSE:DGE
|
UK |
|
ADTRAN Inc
NASDAQ:ADTN
|
US |
|
Darling Ingredients Inc
NYSE:DAR
|
US |
|
Aya Gold & Silver Inc
TSX:AYA
|
CA |
Wall St Price Targets
Price Targets Summary
Samsung Biologics Co Ltd
According to Wall Street analysts, the average 1-year price target for Samsung Biologics Co Ltd is 2 224 987.2758 KRW with a low forecast of 1 919 000 KRW and a high forecast of 2 489 550 KRW.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is Samsung Biologics Co Ltd's stock price target?
Price Target
2 224 987.2758
KRW
According to Wall Street analysts, the average 1-year price target for Samsung Biologics Co Ltd is 2 224 987.2758 KRW with a low forecast of 1 919 000 KRW and a high forecast of 2 489 550 KRW.
What is the Revenue forecast for Samsung Biologics Co Ltd?
Projected CAGR
15%
Over the last 11 years, the compound annual growth rate for Revenue has been 41%. The projected CAGR for the next 3 years is 15%.
What is the Operating Income forecast for Samsung Biologics Co Ltd?
Projected CAGR
16%
The compound annual growth rate for Operating Income over the next 4 years is 16%.
What is the Net Income forecast for Samsung Biologics Co Ltd?
Projected CAGR
12%
The compound annual growth rate for Net Income over the next 3 years is 12%.
